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Abstract
Background: Duchenne muscle dystrophy (DMD) is one of the most common lethal genetic diseases of children
worldwide and is 100% fatal. Steroids, the only therapy currently available, are marred by poor efficacy and a high
side-effect profile. New therapeutic approaches are urgently needed.
Methods: Here, we leverage PGC-1α, a powerful transcriptional coactivator known to protect against dystrophy in
the mdx murine model of DMD, to search for novel mechanisms of protection against dystrophy.
Results: We identify heme oxygenase-1 (HO-1) as a potential novel target for the treatment of DMD. Expression of
HO-1 is blunted in the muscles from the mdx murine model of DMD, and further reduction of HO-1 by genetic
haploinsufficiency worsens muscle damage in mdx mice. Conversely, induction of HO-1 pharmacologically protects
against muscle damage. Mechanistically, HO-1 degrades heme into biliverdin, releasing in the process ferrous iron
and carbon monoxide (CO). We show that exposure to a safe low dose of CO protects against muscle damage in
mdx mice, as does pharmacological treatment with CO-releasing molecules.
Conclusions: These data identify HO-1 and CO as novel therapeutic agents for the treatment of DMD. Safety
profiles and clinical testing of inhaled CO already exist, underscoring the translational potential of these
observations.
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Background
Duchenne muscular dystrophy (DMD) is a common (1 in
3500 boys), X-linked recessive, inexorably lethal disease
characterized by acute phases of muscular degeneration
and insufficient compensatory regeneration [1]. Diagnosis
occurs early in life from noticeable walking difficulty. The
disease is 100% fatal. Death occurs by the early twenties
from respiratory or cardiac failure caused by damage to the
heart and diaphragm muscles. There is no known cure for
DMD. DMD is caused by mutations in the dystrophin
(DMD) gene that lead to loss of functional protein.
Dystrophin protein is a part of the large dystrophin-
glycoprotein complex that links the inner cytoskeleton of
muscle cells with the extracellular basal lamina. Loss of
dystrophin leads to dysfunction and necrosis of mature
muscle cells including an increase in membrane damage
from mechanical or hypo-osmotic stress and decreased
function of plasma membrane proteins including neuronal
nitric oxide synthase (nNOS) [1–4]. Though the genetic
cause of DMD is known, how dystrophin mutations lead to
muscle damage is incompletely understood, nor how to re-
verse the process. Significant efforts have focused recently
on achieving total cure for DMD, including approaches
such as exon skipping and most recently CRISPR-mediated
genome editing [5–7], but significant hurdles persist. A
complementary approach, which may be more imminently
tractable, is the possibility of altering the natural course of
the disease, via inhibiting degeneration and/or stimulating
regeneration of muscle cells.
The transcriptional coactivator peroxisome proliferator-
activated receptor gamma coactivator 1-α (PGC-1α) is a
powerful activator of broad metabolic programs in various
tissues [8–10]. In the skeletal muscle, PGC-1α strongly
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induces mitochondrial biogenesis, resulting in mice resist-
ant to fatigue [11, 12]. A number of years ago, crossing
mice that transgenically express PGC-1α in the skeletal
muscle into the dystrophin-deficient mice (mdx) back-
ground, a well-established murine model of DMD,
revealed impressive protection against dystrophy [13]. The
protection has widely been presumed to result from the
strong PGC-1α-mediated induction of neuromuscular
junction genes and, in particular of utrophin, a homolog
of dystrophin that is known to be protective in DMD
models. However, we recently generated mice with
muscle-specific expression of peroxisome proliferator-
activated receptor gamma coactivator 1-β (PGC-1β), a
homolog of PGC-1α, and found that PGC-1β did not
induce neuromuscular junction (NMJ) genes or utrophin
itself and yet was equally protective against dystrophy in
the mdx model [14]. This suggested that utrophin was not
the key mediator of protection in the PGC-1α transgenic
mice. We formally tested this notion by crossing the
PGC-1α-expressing mice into an mdx/utrophin−/− back-
ground, which at baseline reveal much more pronounced
dystrophy, including blunted growth, kyphosis, and early
lethality. PGC-1α significantly improved the dystrophic
phenotype of these mice, including early lethality [14].
PGC-1α thus potently protects against dystrophy, but not
via utrophin.
How does PGC-1α protect against muscle dystrophy,
if not via utrophin? We investigate here two possibilities:
induction of vasculature and induction of Hmox1, the
gene encoding for heme oxygenase (HO-1).
Methods
Animals
All animal experiments were performed according to the
procedures approved by the Beth Israel Deaconess
Medical Center’s Institutional Animal Care and Use Com-
mittee. All experimental animals used were male. C57BL/
10ScSn-Dmdmdx/J mice (mdx mice) were obtained from
Jackson Laboratories. These mice were crossed with
muscle-specific PGC-1α transgenic mice (MCK-PGC-1α),
described previously [11]; muscle-specific PGC-1β
transgenic mice (MCK-PGC-1β) described previously [15];
or mice with inducible PGC-1α (Ind_PGC-1α) that pos-
sess the muscle-specific tetracycline-dependent activator
(MCK-tTA), described previously [16], and the PGC-1α
coding region under control of the tet-response element
promoter (TRE-PGC-1α) transgenic genes, described
previously [16]. All of these mice were in C57BL/6
background; progeny were therefore in mixed C57BL/6
and C57BL/10 background. For all experiments,
littermates were used as controls, and male animals were
evaluated. mdx, mdx/MCK-PGC-1α, mdx/MCK-PGC-1β,
and mdx/Ind_PGC-1α were sacrificed at 9 weeks of age
(n = 5 transgenic, 5 controls). Male HMOX+/− mice
(FVB.129S2(B6)-Hmox1tm1Poss/J) were obtained from
Jackson Laboratories (JAX008311) and crossed with
female C57BL/10ScSn-Dmdmdx/J mice. HMOX+/−/mdx
animals are therefore in mixed background, and, again,
litter-mates were strictly used for control (n = 8 experi-
mental; 8 control). Ind_tsFLT mice, engineered to express
in skeletal muscle inducible sFlt1 in a tet-OFF fashion,
have been used by us previously [17] and were generated
by crossing transgenic mice expressing tet-inducible sFlt1,
previously described [18], with transgenic mice expressing
muscle-specific expression of the tTA transactivator, as
above. All doxycycline-responsive mice are in a tet-OFF
system, and mice were maintained on tetracycline chow
throughout pregnancy and development, and switched to
regular chow at 5 weeks of age, followed by evaluation
and harvesting at 9 weeks of age. Littermate controls were
used for all experiments.
Protoporphyrin IX cobalt chloride (CoPP) (Sigma-
Aldrich) was dissolved in NaOH (0.2 M) and then adjusted
to pH 7.6 with HCl. 10 mg/kg/day of dissolved CoPP was
injected three times a week intra-peritoneally into mdx
male mice from 5 to 9 weeks of age (n = 10 CoPP; 7 con-
trol). Age-matched mdx control mice were injected with
HCl-neutralized NaOH (pH 7.6). Male mdx mice were
exposed to carbon monoxide (CO) gas at a concentration
of 250 ppm for 1 h a day, 5 days a week, for 4 weeks total
from 5 to 9 weeks of age. Mice were then sacrificed. Con-
trol mdx mice were placed in an equivalent-sized plexiglass
box for 1 h a day (n = 8 CO, 8 control). Male mdx mice
were injected with 2.5 mg/kg/day of CO-releasing molecule
A1 (CORM-A1) from 5 to 9 weeks of age. CORM-A1 was
dissolved 5 min before injection freshly each day. Inacti-
vated CORM-A1 was obtained by dissolving CORM-A1
and then piping nitrogen through the solution for 15 min
to activate release of all CO. Inactivated CORM-A1 was
made fresh every 2 weeks (n = 6 active CORM-A1; 8 inacti-
vated CORM-A1).
Cell culture
Primary satellite cells were isolated and cultured from the
entire hind limb of wild-type/control (WT) mice as
previously described [19]. Cells were differentiated into
myotubes using DMEM with 5% horse serum for 72 h.
Cells were then infected with control (GFP) adenovirus
(WT) or recombinant PGC-1α adenovirus (Ad-PGC-1α))
at multiplicity of infection of 10–30. Ad-PGC-1α contains
PGC-1α expressed under control of the CMV promoter
and has been described previously [20]; we have used it
extensively, with robust induction of PGC-1α expression
[17, 21, 22]. Cells were analyzed 48 h later.
Evans blue injection and histological analysis
For Evans blue assay, mice were injected with 1% solution
i.p. at a final concentration of 1% volume to body weight
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16 h priors to sacrifice. Tissues were dissected and embed-
ded in OCT compound (VWR) and flash-frozen. Evans
blue was analyzed by fluorescence microscopy. Percentage
area of Evans blue extravasation in the gastrocnemius was
quantified, using ImageJ (NIH), by measuring the area of
extravasation in at least ten ×200 images per condition. For
purposes of quantifying central nuclei and fiber sizes,
sections were stained with rabbit polyclonal anti-laminin
antibody (Abcam, ab11575) in order to establish fiber
boundaries. We used two different staining techniques to
calculate centralized nuclei: (i) frozen sections were stained
with anti-laminin and counterstained with DAPI; (ii) tissue
was dehydrated and embedded in paraffin and sectioned
before H&E staining. In either case, 20 images were taken
at ×200 and number of centralized nuclei fibers to total fi-
bers was counted in a blinded fashion. At least 500 fibers
across sections from different animals were counted for
each condition. For fiber sizes, all sizes were measured
using ImageJ software, and 50 bins were created spanning
the smallest to largest fiber size across the two comparison
groups. For each group, the % of fibers in each bin was then
calculated and plotted. Statistical comparison between
groups was done using the Mann-Whitney U test.
Serum creatine kinase assay
The blood was collected and serum isolated using heparin-
coated collection tubes, either by heart puncture or cheek
bleed. Blood was collected and spun down at maximum
speed in heparinized tubes, after which serum was col-
lected, flash-frozen, and stored at −80. Serum creatine kin-
ase activity was then determined, simultaneously for all
samples in a given experiment, with a Creatine Kinase-SL
Assay Kit (Diagnostic Chemicals Limited).
Real-time PCR
Total RNA was isolated from mouse tissue using the
TRIzol (Invitrogen) reagent, while RNA from cultured cells
were isolated using the Turbocapture (Qiagen) method.
Samples for real-time PCR analyses were reverse tran-
scribed (Applied Biosystems), and quantitative real-time
PCRs were performed on the cDNAs in the presence of
fluorescent dye (SYBR green; Bio-Rad). Relative expression
levels were determined using the comparative cycle thresh-
old method. All q-RT-PCR data were normalized to the
average expression of three different housekeeping genes,
TATA-binding protein (TBP), hypoxanthine phosphoribo-
syltransferase 1 (HPRT), and β-actin, as we have described
































Protein from gastrocnemius (100 μg) was run on a 4–20%
polyacrylamide gel, transferred to nitrocellulose mem-
brane, and blotted for heme-oxygenase I using an anti-
HMOX1 antibody (ADI-SPA-896, Enzo Life Sciences),
followed by goat anti-rabbit antibody conjugated to horse-
radish peroxidase (7074, Cell Signaling Technology Inc),
followed by detection using ECL Reagent (Cell Signaling
Technology Inc). As control, blot was stripped and probed
with anti-pan-actin antibody (Cell Signaling Technology
Inc). Blots were visualized and quantified with Biorad
Image-Lab Software.
Patient biopsies
Biopsies from patients were kindly obtained from the lab
of Dr. Louis Kunkel. Biopsies were taken of the vastus
lateralis of normal controls and latissimus dorsi of DMD
muscle. The WT biopsies were from healthy male
subjects ranging from 13 to 32 years of age. Biopsies
from DMD patients were from 12 to 20 years of age with
different genetic defects in the dystrophin gene.
Statistical analysis
The data are presented as means ± SEM. Statistical ana-
lysis was performed with Student’s t test for all in vitro
experiments and ANOVAs for all in vivo experiments.
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Fiber size comparisons were done using the Mann-
Whitney U test. P values of <0.05 were considered statis-
tically significant.
Results
Inhibition of VEGF signaling worsens dystrophy
We showed a number of years ago that PGC-1α power-
fully induces angiogenesis in the skeletal muscle [21, 24].
The new vessels are functional, patent, non-leaky, and
carry blood [25]. PGC-1α thus coordinately induces the
consumption of fuel and oxygen (in mitochondria) with
the delivery of fuel and oxygen (via blood vessels). Re-
duced blood flow and ischemia have been proposed to
play an important role in DMD models, in part leading
to the rationale for the recent use of the vasodilators
sildenafil and tadalafil in clinical trials (with, thus far,
mixed results). We therefore reasoned that perhaps,
PGC-1α exerts its potent anti-dystrophic effects via
dramatic increase in vascular density and blood flow. To
test this notion, we first generated, in the mdx back-
ground, mice that express, in the muscle only and in a
tetracycline-inducible manner, a locally secreted soluble
VEGF receptor 1 (also known as soluble Fms-like
tyrosine kinase 1, sFlt1). This VEGF “trap” neutralizes
extracellular VEGF signaling and blocks angiogenesis.
These mice, which we name Ind_tsFLT, were generated
by breeding transgenic mice expressing tetracycline-
inducible sFlt1, a kind gift of Eli Keshet [18]), with trans-
genic mice expressing muscle-specific expression of the
tTA transactivator, also previously described [16], all in
the mdx background (Fig. 1a). Thus, the mice express
the VEGF trap only in the skeletal muscle and only in
the absence of doxycycline. Mice were fed doxyclycine-
containing chow throughout pregnancy, development,
and weaning, to maintain the VEGF trap suppressed. At
5 weeks of age, mice were changed to normal chow,
leading to robust expression of the VEGF trap in the
skeletal muscle (Fig. 1b). Importantly, by virtue of a
heparin-binding domain, the VEGF trap does not leak
into the circulation or to other tissues (Fig. 1b), as
originally reported [18]. Littermate mice that did not
contain the sFLT transgene were used as controls and
were similarly maintained on doxy-chow and released to
normal chow at 5 weeks, thus controlling for any effects
of doxycycline chow.
Mdx mice undergo cycles of muscle degeneration and
regeneration, most marked during the first 3–10 weeks
of life. Muscle degeneration can be detected during this
period in a number of fashions, including accumulation
of muscle creatine kinase (CK) in serum, and extra-
vasation of Evans blue dye, which normally remains




Fig. 1 Inhibition of VEGF signaling worsens dystrophy. a Dual transgenic system to express both sFlt1 in the muscle only and only in absence of
doxycycline. MCK muscle creatine kinase promoter, tTA tetracycline-suppressed transactivator, TRE tTA-responsive promoter. b Western blotting of
sFlt1 demonstrating induction of sFlt1 in the muscle (top) and absence of spilling of sFlt1 into the circulation (bottom). c–e Serum creatine kinase
levels (c), % Evans blue dye extravasation (d), and % central nuclei in gastrocnemius muscle (e) from mdx mice bearing the indicated transgenes.
Scale bar = 50 μm. n = 8. *P < 0.05, Student’s t test. Error bars indicate ±SEM
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induction of the VEGF trap in the skeletal muscle of
mdx mice led to a near doubling of serum CK levels
(Fig. 1c). This was accompanied by marked increase in
EBD extravasation (Fig. 1d). Following muscle degener-
ation, cycles of regeneration are driven by the activation of
resident progenitor cells and their fusion with degenerat-
ing myofibers. This process can be detected by the appear-
ance and accumulation of central nuclei, which otherwise
normally reside in the periphery of fibers, as well as the
accumulation of small regenerated myofibers. Consistent
with the increase in muscle damage, induction of the
VEGF trap in the skeletal muscle of mdx mice markedly
increased the accumulation of central nuclei (Fig. 1e).
These data demonstrate that suppression of VEGF signal-
ing in mdx mice markedly worsens muscle dystrophy in
this model, consistent with the notion that impaired
vascular homeostasis worsens dystrophy.
PGC-1α protects against dystrophy independently of
angiogenesis
Can suppression of VEGF signaling abrogate the ability
of PGC-1α to improve muscle dystrophy? To test this,
we used a triple transgenic model, in the background of
the mdx model, whereby both PGC-1α and the VEGF
trap are simultaneously induced in the skeletal muscle
upon removal of doxycycline (Fig. 2a). This was achieved
by crossing Ind_tsFlt mice with mice containing a third
transgene encoding for tetracycline-inducible PGC-1α, a
kind gift from Dr. Dan Kelly [16]. Therefore, in these
triple transgenic mice, the VEGF trap and PGC-1α are
simultaneously induced, only in the skeletal muscle and
only in the absence of doxycycline. Induction of PGC-1α
alone (without the VEGF trap) led to a robust induction of
vascular density, which was completely abrogated with co-
induction of the VEGF trap (Fig. 2b), as we have shown
before in a non-dystrophic context [17], thus demonstrat-
ing the effectiveness of suppression of angiogenesis in this
model. We therefore used this system to test the hypoth-
esis that PGC-1α improves muscle dystrophy by virtue of
stimulating vascular density. If true, then induction of
PGC-1α in the context of simultaneously induced VEGF
trap should show no improvement compared to the VEGF
trap alone. Strikingly, however, despite the complete block
in angiogenesis, the induction of PGC-1α was still able to
protect against dystrophy in the presence of the VEGF
trap, as shown by reduction of circulating CK (Fig. 2c), re-
duced extravasation of EB dye (Fig. 2d), and reduced accu-
mulation of central nuclei (Fig. 2e). Thus, these data show
A B
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Fig. 2 PGC-1α protects against dystrophy independently of angiogenesis. a Tri-transgenic system to express both PGC-1α and sFlt1 in the muscle
only and only in absence of doxycycline. MCK muscle creatine kinase promoter, tTA tetracycline-suppressed transactivator, TRE tTA-responsive
promoter. b PGC-1α-induced angiogenesis is blocked in the presence of sFlt1: capillary density, identified by CD31 staining, in muscle cross
sections from mdx mice bearing the indicated transgenes; quantification is on the right. c–e Despite absence of angiogenesis, PGC-1α protects
against dystrophy: serum creatine kinase levels (c), sample Evans blue staining in diaphragm (d), and % central nuclei in gastrocnemius muscle
(e) from mdx mice bearing the indicated transgenes. n = 8. *P < 0.05 versus mdx alone, #P < 0.05 versus mdx/Ind_PGC-1α, Student’s t test. Scale
bar = 50 μm. Error bars indicate ±SEM
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that suppression of VEGF signaling in mdx mice does not
prevent PGC-1α from protecting against muscle dys-
trophy in this model.
HO-1 expression is reduced in dystrophic muscle and is
rescued by PGC-1α
How does PGC-1α protect against muscle dystrophy, if
not via utrophin, via NMJ induction, or via increases in
vascular density? We reasoned that identifying other
pathways induced by PGC-1α may point to novel path-
ways involved in protection against dystrophy. In search
of genes induced by PGC-1α that may have protective
roles in the skeletal muscle, our attention was caught by
Hmox1, the gene encoding for heme oxygenase (HO-1),
as a gene of interest. HO-1 degrades the cyclic pros-
thetic group heme, liberating ferrous iron and yielding
biliverdin and gaseous carbon monoxide (CO) in the
process. Heme is abundant in the skeletal muscle,
present for example in myoglobin and mitochondrial
cytochromes. A growing literature supports a protective
role for HO-1 in various contexts, though it remains un-
clear to what extent these benefits accrue from the deg-
radation of toxic heme, the generation of anti-oxidant
biliverdin, and/or protective effects of CO [26–28]. We
therefore decided to focus attention on HO-1. Interest-
ingly, the Kunkel lab recently identified small molecule
inducers of HO-1 as protective in a zebrafish model of
DMD, although subsequent experiments raised into
question if protection involved increasing HO-1, as
originally proposed [29, 30].
Consistent with previous reports, we find induction of





Fig. 3 HO-1 expression is reduced in dystrophic muscle, and PGC-1α rescues HO-1 expression. a Relative gene expression of the indicated genes in the
indicated muscle beds from transgenic mice expressing PGC-1α in the skeletal muscle (MCK-PGC-1a), versus controls. b Relative gene expression of the
indicated genes in myotubes expressing adenovirus-driven PGC-1α (ad_PGC-1a), versus GFP controls. c, d Relative gene expression (c) and protein
expression (d) of HO-1 in the muscle from mdx mice, versus controls. Quantification is shown on the right. e Relative gene expression of the indicated
genes in the muscle from patients with DMD, versus matched controls. N= 3 per group. f, g Relative gene expression (f) and protein expression (g) of
HO-1 in the muscle from mdx/MCK-PGC1a and mdx/MCK-PGC-1b transgenic mice, versus mdx alone. Quantification of protein expression is shown on the
right. n= 5. Red bars highlight HMOX1 data. *P< 0.05, Student’s t test. Error bars indicate ±SEM
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and utrophin, in quadriceps, gastrocnemius, and tibialis
anterior, of mice that transgenically express PGC-1α in
the skeletal muscle under control of the muscle creatine
kinase promoter (MCK-PGC-1α mice) (Fig. 3a). In
addition, we noted a strong threefold induction of
Hmox1. Adenoviral delivery of PGC-1α to differentiated
primary myotubes induced Hmox1 fourfold (Fig. 3b), in-
dicating that the induction of Hmox1 by PGC-1α is cell
autonomous. To assess the role for HO-1 in muscle dys-
trophy, we first tested its expression in the muscle from
mdx mice. As shown in Fig. 3c, d, both transcript and
protein expression of HO-1 were depressed more than
50% in the muscle from these mice, compared to age-
matched, sex-matched, C57/BL10 mice, purchased from
the same vendor and bred and maintained in the same
mouse facility and suite as the mdx mice. Evaluation of
human muscle biopsies revealed a strong trend for de-
pressed expression of HO-1 (Fig. 3e, P < 0.07) (although
these data must be interpreted with caution, in light of
small number of samples and variability of biopsy site).
Transgenic expression of PGC-1α in the mdx background
reversed this inhibition, inducing Hmox1 transcript and
HO-1 protein more than twofold compared to littermate
controls not expressing the transgene (Fig. 3f, g). Trans-
genic expression of PGC-1β in the skeletal muscle also in-
duced HO-1 more than twofold in mdx mice compared to
littermate controls not expressing the transgene (Fig. 3g).
These data indicate that HO-1 expression is depressed in
muscle dystrophy and that induction of PGC-1α can
reverse the repression of HO-1.
Increasing HO-1 expression ameliorates muscle damage,
while decreased HO-1 expression exacerbates muscle
damage in mdx mice
In light of the known beneficial effects of PGC-1α in
mdx mice, the data above suggested that induction of
HO-1 may improve dystrophy in this model. To test this
notion, we treated mdx mice with cobalt protoporphyrin
(Co-PP), a well-established and powerful inducer of






Fig. 4 Induction of HO-1 protects against dystrophy. a Model. b, c Relative gene expression (b) and protein expression (c) of HO-1 in the muscle
from mdx mice treated with Co-PP, versus vehicle. Quantification is shown on the right in c. d–g Serum creatine kinase levels (d), and % Evans
blue extravasation (e), fiber size distribution (f), and % central nuclei (g) in gastrocnemius muscle from mdx mice treated with Co-PP, versus ve-
hicle. n = 8. *P < 0.05, Student’s t test. Scale bar = 50 μm. Error bars indicate ±SEM
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injections of Co-PP three times a week for 4 weeks led
to robust induction of HO-1 mRNA and protein expres-
sion measured in the gastrocnemius muscle (Fig. 4a–c).
Strikingly, accumulation of CK in the serum of mdx
mice was reduced by 50% (Fig. 4d) by treatment with
Co-PP. This was accompanied by visible inhibition of
Evans blue dye extravasation in the diaphragm and
gastrocnemius (Fig. 4e). Consistent with the inhibition
of muscle damage, treatment of mdx mice with Co-PP
preserved larger myofiber size (Fig. 4f ) and markedly
reduced the accumulation of central nuclei (Fig. 4g).
These data demonstrate that treatment with Co-PP and
induction of HO-1 in mdx mice markedly improves
muscle dystrophy in this model.
The data above indicate that induction of HO-1 is suffi-
cient to protect against muscle dystrophy. To test if HO-1
is also necessary for endogenous adaptation to dystrophy,
we crossed mice heterozygous null at the Hmox1 locus
into the mdx background (Fig. 5a). Mice lacking HO-1
have been described [32]. Homozygous mice are
sometimes viable but display numerous phenotypes, in-
cluding anemia, abnormal iron storage and metabolism,
and chronic inflammation. On the other hand, heterozy-
gous mice are largely normal at baseline. As shown in
Fig. 5b, c, the expression of HO-1 mRNA and protein is
decreased by 50% in heterozygous mice, indicating
haploinsufficiency at this locus. The mice are thus useful
to test the role of HO-1 in adaptation to the mdx back-
ground. No abnormalities were seen in the muscle from
Hmox1+/− mice at baseline. On the other hand, as shown
in Fig. 5d, accumulation of CK in the serum was sig-
nificantly worsened in Hmox1+/−/mdx mice, compared to
mdx alone. This was accompanied by visibly more Evans
blue dye extravasation in the diaphragm and gastrocne-
mius (Fig. 5e). Evidence of compensatory increases in re-
generation was seen with significantly smaller fiber sizes
(Fig. 5f) and significantly more central nuclei (Fig. 5g).
Haploinsufficiency at the Hmox1 locus thus worsens
dystrophy in mdx mice, indicating that HO-1 is required





Fig. 5 Suppression of HMOX1 worsens muscle dystrophy. a mdx mice were crossed with HMOX1 heterozygotes. b, c Relative gene expression (b)
and protein expression (c) of HMOX1 in the muscle from mdx and mdx hmox+/− mice. Quantification is shown on the right in c. d–g Serum
creatine kinase levels (d), and % Evans blue extravasation (e), fiber size distribution (f), and % central nuclei (g) in gastrocnemius muscle from mdx
versus mdx hmox+/− mice. n = 8. *P < 0.05, Student’s t test. Scale bar = 50 μm. Error bars indicate ±SEM
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Carbon monoxide treatment ameliorates muscle damage
in mdx mice
By what mechanism does HO-1 improve dystrophy?
HO-1 degrades the cyclic prosthetic group heme,
liberating ferrous iron and yielding biliverdin and CO
gas in the process (Fig. 6a). The benefits of HO-1
could in theory accrue from the degradation of toxic
heme, the generation of anti-oxidant biliverdin, and/or
protective effects of CO itself. We therefore tested if
delivery of CO alone to mdx mice could confer
protection against dystrophy. We achieved delivery of
CO by two methods: first, inhalation of low-dose CO
(250 ppm, 0.025%) and, second, by using CO-releasing
molecules (CO-RMs). CORM-A1 is a water soluble
CO-releasing molecule with a relatively long half-life
(21 min at 37 °C, pH 7.4 [33]). Exposure of mdx mice
to ambient low-dose CO for 1 h/day for 4 weeks led to
a dramatic improvement in dystrophy, evidenced by
marked improvement of Evans blue extravasation in
diaphragm, and a 40% reduction in circulating creatine
kinase levels (Fig. 6b–d). Hmox1 expression was not
induced by CO (Fig. 6e), consistent with mechanistic
activity downstream of HO-1. Interestingly, myofiber
sizes were not altered with CO exposure (Fig. 6f ). In
addition, central nuclei were slightly increased
(Fig. 6g), suggesting that CO may also affect myopro-
genitor proliferation or differentiation.
Treatment of mdx mice with daily injections of
CORM-A1 for 4 weeks recapitulated all of the findings
seen with inhaled CO, including marked improvements
in dystrophy, with a dramatic reduction of Evans blue ex-
travasation, and reduced circulating CK levels (Fig. 7a–c),
unaltered expression of Hmox1 (Fig. 7d), unaltered myofi-
ber sizes (Fig. 7e), and slight increase in central myonuclei
(Fig. 7f).
Together, these data indicate that delivery of CO, either
via inhalation or via pharmaceutical delivery, strongly






Fig. 6 Inhaled low-dose carbon monoxide protects against dystrophy. a Schematic of HO-1 enzymatic action. b Mice were placed in chambers containing
250 ppm CO for 1 h per day. c, d Serum creatine kinase (c) and sample Evans blue staining in diaphragm and % Evans blue extravasation in gastrocnemius
(d) in mdx mice exposed to CO versus air alone. e Relative expression of the indicated genes in gastrocnemius from mdx mice exposed to CO versus air
alone. f, g Fiber size distribution in gastrocnemius (f) and % central nuclei in gastrocnemius muscle (g) from mdx mice exposed to CO versus air alone.
n= 8. *P< 0.05, Student’s t test. Scale bar= 50 μm. Error bars indicate ±SEM
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Discussion
We have leveraged here the transcriptional coactivator
PGC-1α to identify a novel pathway, involving the heme
oxygenase enzyme and its enzymatic product carbon
monoxide, as potent protective agents against dystrophy.
One of the more appealing and transformative aspects
of the work is its potential imminent translatability to
the clinical setting. CO has an understandably nefarious
public image, but the toxicity of CO occurs at doses or-
ders of magnitude higher than those used here. Indeed,
CO is produced endogenously by HO-1 under normal
physiology. The safety of CO in humans has been dem-
onstrated in phase I dose escalation with no evidence of
toxicity (clinicaltrials.gov NCT01050933, Otterbein per-
sonal communication, and [26]). Inhaled CO was also
found to be safe in patients with COPD [34]. There are
currently ongoing clinical trials of inhaled CO for
treatment of adult and neonatal pulmonary hypertension
(NCT01523548 and NCT01818843, respectively), ARDS
(NCT02425579), post-operative ileus (NCT01050712),
idiopathic pulmonary fibrosis (NCT01214187), and
cardiac mitochondrial dysfunction (NCT01727167),
extensively underscoring the accepted toxicity profile of
CO. Importantly, in our experiments and in all of the
above studies, inhaled CO is delivered only in intermit-
tent doses, in our case 1 h a day. Translation to the
clinic is therefore pragmatically feasible. Patients with
DMD often have reduced respiratory capacity, in which
case, the dose of delivery CO could be adjusted by
measuring diffusing capacity of the lung for carbon
monoxide (DLCO), a widely used clinical test. Alterna-
tively, CO-releasing molecules (CO-RMs) may also serve
as bioavailable alternatives to inhaled CO, which would
both facilitate delivery and allay fears of inhaling a
gaseous therapeutic. Our work thus suggests that deliv-
ery of CO, either by inhalation of by CO-RMs, could be
ready for clinical trials, and/or trials in large animals, to
test for efficacy in the treatment of Duchenne muscular
dystrophy, and perhaps other dystrophies as well.
How does heme oxygenase protect against dystrophy?
Heme oxygenase degrades the cyclic prosthetic group






Fig. 7 Delivery of carbon monoxide via small molecules protects against dystrophy. a Mice were treated daily with 2.5 mg/kg CORM-A1. b, c Sample
Evans blue staining in diaphragm and % Evans blue extravasation in gastrocnemius (b) and serum creatine kinase (c) in mdx mice treated with CORM-A1
versus vehicle. d Relative expression of the indicated genes in gastrocnemius from mdx mice treated with CORM-A1 versus vehicle. e, f Fiber size
distribution (e) and % central nuclei (f) in gastrocnemius muscle from mdx mice treated with CORM-A1 versus vehicle. n= 8. *P< 0.05, Student’s t test.
Scale bar= 50 μm. Error bars indicate ±SEM
Chan et al. Skeletal Muscle  (2016) 6:41 Page 10 of 12
gaseous CO (Fig. 3a). The protective effects of HO-1
could therefore in principle stem from reductions of
toxic heme or from beneficial effects elicited by biliver-
din, iron, or CO. Mechanistically, we show here that CO
alone is sufficient to protect against muscle dystrophy.
Additional involvement by the other enzymatic products
is also possible, as is suggested for example by the
observation that treatment with CO or CORM both led
to protection from damage, as determined by CK and
EBD leak, but did not lead to larger fibers, in contrast to
treatment with HO-1 activators.
How CO itself protects against dystrophy is also of inter-
est and will be the subject of future studies. One possibility
is the observation that CO can, in some contexts, promote
the formation of NO [26]. NO has been espoused as benefi-
cial in models of dystrophy, perhaps in part via vasodilation
and improved local ischemia [3, 4, 35]. Exposure to CO can
also change cellular bioenergetics and increase oxygen
consumption [36, 37] and can increase mitochondrial bio-
genesis in the muscle from humans and animals [38, 39].
CO-induced mitochondrial biogenesis may thus contribute
to protection against dystrophy and if so may constitute a
positive feedback loop with PGC-1α expression.
Although we have focused our attention here on heme
oxygenase as a novel therapeutic opportunity, the anti-
dystrophy protection that is afforded by PGC-1α is likely
multifactorial and is unlikely limited only to the induction
of heme oxygenase. Because complete deletion of Hmox1
has diffuse effects, testing the relative contribution of the
HO-1 system to PGC-1α-mediated protection will require
introducing muscle-specific deletion of Hmox1 into
transgenic PGC-1α mice in the mdx background.
Conclusions
In summary, our work highlights a new and actionable
approach to the treatment of patients with DMD, in-
cluding the appealing possibility that low-dose inhalation
of CO could provide a novel and simple therapy for this
devastating disease.
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